Mubadala Investment Company’s Recursion Pharmaceuticals RXRX Stock Holding History

Mubadala Investment Company’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,985,927	Closed	-$63.4M	–	90
2025 Q3	$63.4M	Hold	12,985,927	–	–	0.35%	8
2025 Q2	$65.7M	Hold	12,985,927	–	–	0.35%	7
2025 Q1	$68.7M	Hold	12,985,927	–	–	0.39%	6
2024 Q4	$87.8M	Hold	12,985,927	–	–	0.43%	5
2024 Q3	$85.6M	Hold	12,985,927	–	–	0.45%	4
2024 Q2	$97.4M	Hold	12,985,927	–	–	0.39%	6
2024 Q1	$129M	Hold	12,985,927	–	–	0.51%	5
2023 Q4	$128M	Buy	+12,985,927	New	+$92.6M	0.43%	5

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Mubadala Investment Company's RXRX Position: Q4 2025 in Review

Mubadala Investment Company sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 12,985,927 shares — an estimated $63.4M sold.

Mubadala Investment Company first reported a position in RXRX in Q4 2023 and held it in 8 quarters. The position peaked at $129M in Q1 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Mubadala Investment Company reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Mubadala Investment Company sold 12,985,927 Recursion Pharmaceuticals shares in Q4 2025, an estimated $63.4M.
Mubadala Investment Company first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Mubadala Investment Company's Recursion Pharmaceuticals position peaked at $129M in Q1 2024.
332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Mubadala Investment Company's 13F filing for Q4 2025, filed 17 Feb 2026.